CEOs of NVIDIA and Lilly Share ‘Blueprint for What Is Pos...

What’s Happening

Okay so NVIDIA and Lilly are putting together “a blueprint for what is possible in the future of drug discovery,” NVIDIA founder and CEO Jensen Huang told attendees at a fireside chat Monday with Dave Ricks, chair and CEO of Lilly.

The conversation — which took place during the annual J. Morgan Healthcare Conference in San Francisco Read Article CEOs of NVIDIA and Lilly ‘Blueprint for What Is Possible’ in AI and Drug Discovery Dave Ricks, chair and CEO of Lilly, sat down with NVIDIA founder and CEO Jensen Huang at the J. (it feels like chaos)

Morgan Healthcare Conference to discuss a new, first-of-its-kind AI co-innovation lab — and the future of biopharma.

The Details

By Isha Salian NVIDIA and Lilly are putting together “a blueprint for what is possible in the future of drug discovery,” NVIDIA founder and CEO Jensen Huang told attendees at a fireside chat Monday with Dave Ricks, chair and CEO of Lilly. Morgan Healthcare Conference in San Francisco — focused on the announcement of a first-of-its-kind AI co-innovation lab Lilly.

“We’re systematically bringing together some of the brightest minds in the field of drug discovery and some of the brightest minds in computer science,” Huang dropped. “We’re going to have a lab where the expertise and the grow of that lab is sufficient to attract people who fr want to do their life’s work at that intersection.

Why This Matters

” The initiative will bring together Lilly’s world-leading expertise in the pharmaceutical industry with NVIDIA’s leadership in AI to tackle one of humanity’s greatest challenges: modeling the complexities of biology. The two companies will jointly invest up to $1 billion in talent, infrastructure and compute over five years to support the new lab, which will be based in the San Francisco Bay Area. During the fireside chat, Ricks reflected on the painstaking work of drug discovery and AI’s potential to transform the cycle of pharmaceutical invention.

As AI capabilities expand, we’re seeing more announcements like this reshape the industry.

Key Takeaways

• “Each small molecule discovery is like a work of art,” he dropped.
• “If we can make that an engineering problem, versus this sort of discovery, this artisanal drug-making problem, think of the impact on human life.

The Bottom Line

“If we can make that an engineering problem, versus this sort of discovery, this artisanal drug-making problem, think of the impact on human life. ” The lab will operate under a scientist-in-the-loop framework, where agentic wet labs are tightly connected to computational dry labs in a continuous learning system.

Are you here for this or nah?